Two human antibodies to a meningococcal serogroup B vaccine antigen enhance binding of complement Factor H by stabilizing the Factor H binding site

被引:3
|
作者
Sands, Nathaniel A. [1 ,2 ]
Beernink, Peter T. [1 ]
机构
[1] Univ Calif San Francisco, Sch Med, Dept Pediat, Div Infect Dis & Global Hlth, San Francisco, CA 94143 USA
[2] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
SURFACE PROTEIN-A; NEISSERIA-MENINGITIDIS; BACTERICIDAL ANTIBODY; MONOCLONAL-ANTIBODY; ALTERNATIVE PATHWAY; EPITOPE; RESPONSES; IMMUNOGENICITY; INHIBITION; VIRULENCE;
D O I
10.1371/journal.ppat.1009655
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Microbial pathogens bind host complement regulatory proteins to evade the immune system. The bacterial pathogen Neisseria meningitidis, or meningococcus, binds several complement regulators, including human Factor H (FH). FH binding protein (FHbp) is a component of two licensed meningococcal vaccines and in mice FHbp elicits antibodies that inhibit binding of FH to FHbp, which defeat the bacterial evasion mechanism. However, humans vaccinated with FHbp develop antibodies that enhance binding of FH to the bacteria, which could limit the effectiveness of the vaccines. In the present study, we show that two vaccine-elicited antibody fragments (Fabs) isolated from different human subjects increase binding of complement FH to meningococcal FHbp by ELISA. The two Fabs have different effects on the kinetics of FH binding to immobilized FHbp as measured by surface plasmon resonance. The 1.7- and 2.0-angstrom resolution X-ray crystal structures of the Fabs in complexes with FHbp illustrate that the two Fabs bind to similar epitopes on the amino-terminal domain of FHbp, adjacent to the FH binding site. Superposition models of ternary complexes of each Fab with FHbp and FH show that there is likely minimal contact between the Fabs and FH. Collectively, the structures reveal that the Fabs enhance binding of FH to FHbp by altering the conformations and mobilities of two loops adjacent to the FH binding site of FHbp. In addition, the 1.5 angstrom -resolution structure of one of the isolated Fabs defines the structural rearrangements associated with binding to FHbp. The FH-enhancing human Fabs, which are mirrored in the human polyclonal antibody responses, have important implications for tuning the effectiveness of FHbp-based vaccines. Author summary Microbial pathogens bind specific host proteins to invade the host or evade host immunity. The bacterial pathogen meningococcus causes sepsis and meningitis, and binds a protein in the human immune system known as Factor H (FH). FH binding protein (FHbp) is a component of two licensed vaccines and can produce antibodies that block this evasion mechanism. Surprisingly, humans vaccinated with FHbp develop antibodies that enhance FH binding. To understand the biological mechanism, here we show that two human antibody fragments (Fabs) increase binding of human FH to FHbp by changing the binding kinetics. The three-dimensional structures of the two Fabs bound to FHbp reveal that the Fabs enhance FH binding through structural rearrangement in a region of FHbp adjacent to the FH binding site. A better understanding of FH enhancement by human Fabs can inform the continued development of meningococcal vaccines by eliminating the binding sites for such antibodies.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] The modular architecture of meningococcal factor H-binding protein
    Beernink, Peter T.
    Granoff, Dan M.
    MICROBIOLOGY-SGM, 2009, 155 : 2873 - 2883
  • [42] Characterisation of a heparin binding domain in complement factor H
    Clark, SJ
    Higman, VA
    Fernando, A
    Mulloy, B
    Perkins, SJ
    Lea, S
    Sim, RB
    Day, AJ
    MOLECULAR IMMUNOLOGY, 2006, 43 (1-2) : 142 - 143
  • [43] Binding of complement factor H to the nematode Nippostrongylus brasiliensis
    Baker, S
    Wang, H
    Giacomin, PR
    Dent, LA
    Gordon, DL
    MOLECULAR IMMUNOLOGY, 2004, 41 (2-3) : 205 - 206
  • [44] Meningococcal Factor H Binding Proteins in Epidemic Strains from Africa: Implications for Vaccine Development
    Pajon, Rolando
    Fergus, Andrew M.
    Koeberling, Oliver
    Caugant, Dominique A.
    Granoff, Dan M.
    PLOS NEGLECTED TROPICAL DISEASES, 2011, 5 (09):
  • [45] A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens
    Konar, Monica
    Rossi, Raffaella
    Walter, Helen
    Pajon, Rolando
    Beernink, Peter T.
    PLOS ONE, 2015, 10 (06):
  • [46] Heterogeneity in Rhesus Macaque Complement Factor H Binding to Meningococcal Factor H Binding Protein (FHbp) Informs Selection of Primates To Assess Immunogenicity of FHbp-Based Vaccines
    Beernink, Peter T.
    Shaughnessy, Jutamas
    Stefek, Heather
    Ram, Sanjay
    Granoff, Dan M.
    CLINICAL AND VACCINE IMMUNOLOGY, 2014, 21 (11) : 1505 - 1511
  • [47] Monoclonal Antibodies to Meningococcal Factor H Binding Protein with Overlapping Epitopes and Discordant Functional Activity
    Giuntini, Serena
    Beernink, Peter T.
    Reason, Donald C.
    Granoff, Dan M.
    PLOS ONE, 2012, 7 (03):
  • [48] Combined Roles of Human IgG Subclass, Alternative Complement Pathway Activation, and Epitope Density in the Bactericidal Activity of Antibodies to Meningococcal Factor H Binding Protein
    Giuntini, Serena
    Reason, Donald C.
    Granoff, Dan M.
    INFECTION AND IMMUNITY, 2012, 80 (01) : 187 - 194
  • [49] Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen
    Seib, Kate L.
    Scarselli, Maria
    Comanducci, Maurizio
    Toneatto, Daniela
    Masignani, Vega
    EXPERT REVIEW OF VACCINES, 2015, 14 (06) : 841 - 859
  • [50] Bactericidal human monoclonal antibody 1B1 shows specificity for meningococcal factor H binding protein variant 2 and displaces human factor H
    Veggi, Daniele
    Chesterman, Chelsy C.
    Santini, Laura
    Huang, Ying
    Pacchiani, Nicola
    Sierra, Jeannette
    Chen, Lynn
    Laliberte, Jason
    Bianchi, Federica
    Cozzi, Roberta
    Frigimelica, Elisabetta
    Maione, Domenico
    Finco, Oretta
    Bottomley, Matthew J.
    FASEB BIOADVANCES, 2024, 6 (08) : 235 - 248